Phase 3 N=448 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Esophageal Carcinoma
Primary: Overall Survival (OS) — 8.28; 6.24 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=317 Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
Follicular Lymphoma
Primary: Best Overall Response Rate (BORR) for Low Tumor Burden Follicular Lymphoma — 80.2; 79.4 percentage of participants
Phase 3 N=302 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
Encephalitis, Tick-Borne
Primary: Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination — 100; 97.8 Percentage of participants — p=<0.001
Phase 3 N=210 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
Obesity · Overweight · Metabolism and Nutrition Disorder
Primary: Mean Percent Change From Baseline in Body Weight — -14.4; -19.9; -2.4 Percent change — p=<0.001
Phase 3 N=553 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
Macular Edema · Branch Retinal Vein Occlusion
Primary: Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 — 16.9; 17.5 ETDRS Letters — p=0.4978
Phase 3 N=207 Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Covid-19
Primary: Proportion of Subjects Reaching Stabilization or Improvement in Clinical Status at Day 7 — 89; 82 Participants
Phase 3 N=579 Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
Infertility
Primary: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COS — 63.0; 0.0 percentage of participants…
Phase 3 N=597 A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups — 24.92; 25.06; 24.87; 25.12 mmHg
Phase 3 N=729 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion · Hemiretinal Vein Occlusion
Primary: Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 — 16.9; 17.3 ETDRS Letters — p=0.6715
Phase 3 N=598 Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
Primary: • To Evaluate Efficacy of DMB-3115 in Comparison With Stelara — 77.5; 77.85; 87.59; 87.89 percent change in PASI score
Phase 3 N=36 Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
Haemophilia A
Primary: Number of Bleeding Episodes Per Year (Annualised Bleeding Rate) — 0.00; 0.00 Bleeding episodes per year
Phase 3 N=588 Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
Infertility, Female
Primary: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)…
Phase 3 N=541 A Safety Study of 3 Different Bowel Cleansing Preparations
Colonoscopy · Bowel Preparation · Endoscopy
Primary: Percentage of Subjects With Successful Bowel Preparation — 175; 132; 137 Participants — p=<0.001
Phase 3 N=674 Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Malignant Melanoma
Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…
Phase 3 N=492 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 5.6; 5.5 Months — p=0.0122